User menu

Pathologic activation of thrombopoietin receptor and JAK2-STAT5 pathway by frameshift mutants of mouse calreticulin

Bibliographic reference Balligand, Thomas ; Achouri, Y ; Pecquet, Christian ; Chachoua, Ilyas ; Nivarthi, H ; et. al. Pathologic activation of thrombopoietin receptor and JAK2-STAT5 pathway by frameshift mutants of mouse calreticulin. In: Leukemia, Vol. 30, no. 8, p. 1775-1778 (2016)
Permanent URL http://hdl.handle.net/2078.1/173192
  1. Klampfl Thorsten, Gisslinger Heinz, Harutyunyan Ashot S., Nivarthi Harini, Rumi Elisa, Milosevic Jelena D., Them Nicole C.C., Berg Tiina, Gisslinger Bettina, Pietra Daniela, Chen Doris, Vladimer Gregory I., Bagienski Klaudia, Milanesi Chiara, Casetti Ilaria Carola, Sant'Antonio Emanuela, Ferretti Virginia, Elena Chiara, Schischlik Fiorella, Cleary Ciara, Six Melanie, Schalling Martin, Schönegger Andreas, Bock Christoph, Malcovati Luca, Pascutto Cristiana, Superti-Furga Giulio, Cazzola Mario, Kralovics Robert, Somatic Mutations of Calreticulin in Myeloproliferative Neoplasms, 10.1056/nejmoa1311347
  2. Nangalia J., Massie C.E., Baxter E.J., Nice F.L., Gundem G., Wedge D.C., Avezov E., Li J., Kollmann K., Kent D.G., Aziz A., Godfrey A.L., Hinton J., Martincorena I., Van Loo P., Jones A.V., Guglielmelli P., Tarpey P., Harding H.P., Fitzpatrick J.D., Goudie C.T., Ortmann C.A., Loughran S.J., Raine K., Jones D.R., Butler A.P., Teague J.W., O'Meara S., McLaren S., Bianchi M., Silber Y., Dimitropoulou D., Bloxham D., Mudie L., Maddison M., Robinson B., Keohane C., Maclean C., Hill K., Orchard K., Tauro S., Du M.-Q., Greaves M., Bowen D., Huntly B.J.P., Harrison C.N., Cross N.C.P., Ron D., Vannucchi A.M., Papaemmanuil E., Campbell P.J., Green A.R., Somatic CALR Mutations in Myeloproliferative Neoplasms with Nonmutated JAK2, 10.1056/nejmoa1312542
  3. MICHALAK Marek, CORBETT Elaine F., MESAELI Nasrin, NAKAMURA Kimitoshi, OPAS Michal, Calreticulin: one protein, one gene, many functions, 10.1042/bj3440281
  4. Kollmann K, Nangalia J, Warsch W, Quentmeier H, Bench A, Boyd E, Scott M, Drexler H G, Green A R, MARIMO cells harbor a CALR mutation but are not dependent on JAK2/STAT5 signaling, 10.1038/leu.2014.285
  5. Yoshida Hitoshi, Kondo Makoto, Ichihashi Takuji, Hashimoto Naoya, Inazawa Joji, Ohno Ryuzo, Naoe Tomoki, A novel myeloid cell line, Marimo, derived from therapy-related acute myeloid leukemia during treatment of essential thrombocythemia: Consistent chromosomal abnormalities and temporary C-MYC gene amplification, 10.1016/s0165-4608(97)00017-4
  6. Staerk Judith, Defour Jean-Philippe, Pecquet Christian, Leroy Emilie, Antoine-Poirel Hélène, Brett Ian, Itaya Miki, Smith Steven O, Vainchenker William, Constantinescu Stefan N, Orientation-specific signalling by thrombopoietin receptor dimers : Orientation-specific TpoR signalling, 10.1038/emboj.2011.315
  7. Kohlhuber F, Rogers N C, Watling D, Feng J, Guschin D, Briscoe J, Witthuhn B A, Kotenko S V, Pestka S, Stark G R, Ihle J N, Kerr I M, A JAK1/JAK2 chimera can sustain alpha and gamma interferon responses., 10.1128/mcb.17.2.695
  8. Cong L., Ran F. A., Cox D., Lin S., Barretto R., Habib N., Hsu P. D., Wu X., Jiang W., Marraffini L. A., Zhang F., Multiplex Genome Engineering Using CRISPR/Cas Systems, 10.1126/science.1231143
  9. Mashiko Daisuke, Fujihara Yoshitaka, Satouh Yuhkoh, Miyata Haruhiko, Isotani Ayako, Ikawa Masahito, Generation of mutant mice by pronuclear injection of circular plasmid expressing Cas9 and single guided RNA, 10.1038/srep03355
  10. JAK Inhibitor in CALR-Mutant Myelofibrosis, 10.1056/nejmc1400499
  11. Guglielmelli Paola, Bartalucci Niccolò, Rotunno Giada, Vannucchi Alessandro M, Calreticulin: a new horizon for the testing and treatment of myeloproliferative neoplasms, 10.1586/17474086.2014.920250
  12. Rumi E., Pietra D., Ferretti V., Klampfl T., Harutyunyan A. S., Milosevic J. D., Them N. C. C., Berg T., Elena C., Casetti I. C., Milanesi C., Sant'Antonio E., Bellini M., Fugazza E., Renna M. C., Boveri E., Astori C., Pascutto C., Kralovics R., Cazzola M., , JAK2 or CALR mutation status defines subtypes of essential thrombocythemia with substantially different clinical course and outcomes, 10.1182/blood-2013-11-539098